lamotrigine has been researched along with Disease Exacerbation in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis." | 9.14 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010) |
| " In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis." | 5.14 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010) |
| "Treatment with lamotrigine was associated with more rashes (20% vs 5%, P value 0." | 2.52 | Sodium channel blockers for neuroprotection in multiple sclerosis. ( Hao, Z; Wen, J; Yang, C; Zeng, L; Zhang, L, 2015) |
| "Lamotrigine trial in SPMS was a randomised control trial to assess whether partial blockade of sodium channels has a neuroprotective effect." | 1.39 | Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. ( Brenner, R; Furby, J; Giovannoni, G; Gnanapavan, S; Grant, D; Hayton, T; Kapoor, R; Leoni, V; Marta, M; Miller, DH; Morant, S; Palace, J; Teunissen, CE, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pugnaghi, M | 1 |
| Monti, G | 1 |
| Biagini, G | 1 |
| Meletti, S | 1 |
| Gnanapavan, S | 1 |
| Grant, D | 1 |
| Morant, S | 1 |
| Furby, J | 2 |
| Hayton, T | 2 |
| Teunissen, CE | 1 |
| Leoni, V | 1 |
| Marta, M | 1 |
| Brenner, R | 2 |
| Palace, J | 1 |
| Miller, DH | 2 |
| Kapoor, R | 2 |
| Giovannoni, G | 1 |
| Hinc-Kasprzyk, J | 1 |
| Polak-Krzemińska, A | 1 |
| Głowacka, M | 1 |
| Ożóg-Zabolska, I | 1 |
| Yang, C | 1 |
| Hao, Z | 1 |
| Zhang, L | 1 |
| Zeng, L | 1 |
| Wen, J | 1 |
| Kinard, K | 1 |
| Miller, NR | 1 |
| Digre, KB | 1 |
| Katz, BJ | 1 |
| Crum, AV | 1 |
| Warner, JE | 1 |
| Smith, KJ | 1 |
| Altmann, DR | 1 |
| Chataway, J | 1 |
| Hughes, RA | 1 |
| Farooque, P | 1 |
| Goraya, J | 1 |
| Valencia, I | 1 |
| Carvalho, KS | 1 |
| Hardison, HH | 1 |
| Legido, A | 1 |
| Khurana, DS | 1 |
| Comfere, NI | 1 |
| Sartori-Valinotti, JC | 1 |
| Bruce, AJ | 1 |
| Drage, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661] | Phase 2 | 30 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial[NCT00257855] | Phase 2 | 120 participants | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for lamotrigine and Disease Exacerbation
| Article | Year |
|---|---|
Sodium channel blockers for neuroprotection in multiple sclerosis.
Topics: Disease Progression; Female; Humans; Immunosuppressive Agents; Lamotrigine; Male; Middle Aged; Multi | 2015 |
1 trial available for lamotrigine and Disease Exacerbation
| Article | Year |
|---|---|
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
6 other studies available for lamotrigine and Disease Exacerbation
| Article | Year |
|---|---|
Temporal lobe epilepsy exacerbation during pharmacological inhibition of endogenous neurosteroid synthesis.
Topics: 5-alpha Reductase Inhibitors; Anticonvulsants; Brain; Disease Progression; Electroencephalography; E | 2013 |
Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.
Topics: Atrophy; Biomarkers; Brain; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; | 2013 |
The use of plasmapheresis in a 4-year-old boy with toxic epidermal necrosis.
Topics: Anticonvulsants; Child, Preschool; Disease Progression; Drug Resistant Epilepsy; Humans; Lamotrigine | 2015 |
Blepharospasm in children and adolescents.
Topics: Adolescent; Adult; Anticonvulsants; Blepharospasm; Botulinum Toxins, Type A; Cohort Studies; Disease | 2016 |
Early-onset childhood absence epilepsy: is it a distinct entity?
Topics: Age Factors; Age of Onset; Anticonvulsants; Child; Child Development; Child, Preschool; Cohort Studi | 2011 |
Successful treatment of lamotrigine-associated drug hypersensitivity syndrome with intravenous IgG.
Topics: Adult; Anticonvulsants; Disease Progression; Drug Hypersensitivity; Female; Humans; Immunoglobulins, | 2012 |